Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Hitting Home Runs & Grand Slams, Not Loud Outs
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Aggressive Growth Stocks
- Who Wants to Keep "Too Big to Fail" Alive?
- Debt-Ceiling Alarm Bell Tolls
- Avoid These 3 Eurozone ETFs This Summer
- RTI: When Will We Finally See a Pullback?
- Top Stocks with Big Potential Catch-Up Moves
- AWS 5/22: Will Bernanke Show His Hand?
- PFP 5/22: Singular Stock Focus Continues
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/22/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 9.31% |
| SONIC FOUNDR | SOFO | 7.77% |
| TRI TECH HOL | TRIT | 6.62% |
| A M R CP | AAMRQ | 4.52% |
| FLOWERS FOOD | FLO | 4.31% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We are maintaining our Neutral recommendation on Incyte Corporation ( INCY - Analyst Report ) with a target price of $23.00. This is in line with the Zacks #3 Rank (Hold rating) carried by the stock in the short run.
Incyte is a Wilmington, Delaware-based drug discovery and development company focused on oral compounds to treat inflammation and cancer.
We are pleased by the November 2011 U.S. approval and subsequent launch of Jakafi for myelofibrosis (MF). Even though the target population for MF is not very high, we believe that the experience gained from marketing Jakafi should be helpful for future product launches.
The European approval of the drug (to be marketed as Jakavi) for the MF indication is on track with the Committee for Medicinal Products for Human Use (CHMP) recommending its approval. The positive opinion has triggered a milestone payment of $40 million from partner Novartis ( NVS - Snapshot Report ) .
The amount is expected to be received shortly. A further $60 million milestone payment would be due to Incyte following the achievement of reimbursement and pricing approval in certain E.U. nations by Novartis.
Incyte also has a collaboration with another established player, Eli Lilly ( LLY - Analyst Report ) . We believe its association with big pharmaceutical companies will bolster the company’s financial position and experience.
However, apart from Jakafi for the polycythemia vera indication, the other candidates are several years away from hitting the market. Any hiccup in their development process will weigh heavily on the stock.
We note that Incyte suffered a setback with its sheddase inhibitor program when the development of INCB7839 was halted for metastatic breast cancer. Incyte had faced pipeline setbacks earlier, as well. The company terminated the development of a CCR5 antagonist compound INCB9471 (INCB15050) as a once daily oral treatment for HIV/AIDS.
Moreover, since Jakafi was launched for MF only in November 2011, we prefer to adopt a wait-and-watch stance regarding its sales ramp up.
Read the full Analyst Report on INCY
Read the full Analyst Report on LLY
Read the full Snapshot Report on NVS